Advertisement

European Journal of Pediatrics

, Volume 157, Supplement 2, pp S84–S87 | Cite as

Newborn screening for homocystinuria: Irish and world experience

  • E. R. Naughten
  • S. Yap
  • P. D. Mayne

Abstract

Newborn screening for cystathionine β-synthase deficiency (homocystinuria; HCU) was started in the late 1960 s using a bacterial inhibition assay (BIA). At least seven countries have either national or regional screening programmes; 12 programmes are known to have discontinued. The worldwide incidence of HCU is approximately 1 in 335,000 but varies from 1 : 65,000 (Ireland) to 1 : 900,000 (Japan). Methodologies include the BIA, one-dimensional or thin-layer amino acid chromatography and, more recently, tandem mass spectrometry. The BIA diagnostic cut off concentration of blood methionine varies from 67 to 270 μmol/l (10–40 mg/l) with a median of 135 μmol/l (20 mg/l). In Ireland, 25 cases of HCU from 19 families have been identified from 1.58 million newborn infants since 1971; 21 cases were detected through the screening programme. Of the four missed cases, three were breast-fed at the time of blood collection and one was pyridoxine responsive. These findings were in broad agreement with the results from five other programmes, in which approximately one in every five cases was missed by the screening programme. Early hospital discharge, low protein intake, high blood methionine cut-off concentration and pyridoxine responsiveness were all identified as contributing to missed cases.

Key words Homocystinuria Newborn screening 

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • E. R. Naughten
    • 1
  • S. Yap
    • 1
  • P. D. Mayne
    • 2
  1. 1.The Metabolic Unit, The Children’s Hospital, Temple Street, Dublin 1, Ireland, Fax.: +353 1 874 7439IE
  2. 2.National Newborn Screening Laboratory, The Children’s Hospital, Temple Street, Dublin 1, IrelandIE

Personalised recommendations